Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 20, Issue 5, Pages 301-309Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2009.09.006
Keywords
Pharmacogenetics; Imaging genetics; Depression; Anxiety; NPY
Funding
- Deutsche Forschungsgemeinschaft [SFB-TRR-58]
- Rolf-Dierichs-Foundation
Ask authors/readers for more resources
Neuropeptide Y (NPY) has been found to play a role in the pathomechanism of both anxiety and depression. Thus, NPY is a promising candidate in the investigation of the clinical phenotype of anxious depression. Five NPY gene variants were investigated for an influence on antidepressant treatment response in a sample of 256 patients with depression. Additionally, NPY gene impact on amygdala activation during facial emotion processing was analyzed in a subsample of 35 depressed patients. Particularly in anxious depression, the less active NPY rs16147 -399C allele conferred slow response after 2 weeks and failure to achieve remission after four weeks of treatment. The rs16147 C allele was further associated with stronger bilateral amygdala activation in response to threatening faces in an allele-dose fashion. The present results point towards a possible influence of functional NPY gene variation on antidepressant treatment response in anxious depression, potentially conveyed by altered emotional processing. (C) 2009 Elsevier B.V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available